| |
Monday, December 16, 2024 | 1pm ET / 10am PT Join us for an insightful webinar on the evolving privacy landscape impacting pharma marketers. As state laws continue to shape advertising practices, understanding the nuances of compliance and data ethics is crucial. Register now to gain access to expert insights on sustainable privacy strategies and balancing innovation with ethical data use.
|
|
Today’s Big NewsDec 12, 2024 |
|
Wednesday, January 15, 2025 | 12pm ET / 9am PT Sort through the noise and hear from Washington Insiders. This session will offer key insights into the economic and political landscape, guiding your company on how best to prepare for and respond to potential changes in funding opportunities and compliance requirements. Register now.
|
|
| By Fraiser Kansteiner The U.S. watchdog is taking several pharma majors to task over what it says are "unsupported" price increases. But many of the companies have been quick to hit back against ICER’s findings. |
|
|
|
By Gabrielle Masson Despite “encouraging” new data, iTeos Therapeutics is dropping a midstage cancer asset to focus on other programs, a move that will bring the biotech's clinical pipeline down to two investigational meds. |
By Conor Hale The agency expanded its previous premarket approvals for the catheter-based Impella 5.5 and CP pumps developed by Abiomed for children weighing at least 30 kilograms and 52 kilograms for each model, respectively. |
By Andrea Park Over a decade into selling Korlym to treat endogenous hypercortisolism, also known as Cushing syndrome, Corcept Therapeutics is launching its first-ever direct-to-consumer campaign raising awareness of the condition and screening options. |
|
The right funding at the right time is crucial for life sciences companies that want to fuel innovation and scale operations. Download this free whitepaper to drive innovation, expand operations and lead your organization to further success.
|
|
By Angus Liu While under competitive pressure from Novartis and Eli Lilly, Pfizer can tally up a unique trial win for its Ibrance in a niche breast cancer population. |
By Gabrielle Masson Though M&A deal value and volume both declined in biopharma in 2024 compared to the year prior, PwC analysts still believe 2025 will be an active year for the sector. |
By Conor Hale Pleno plans to launch its Raptor benchtop analyzer early next year, and it's poached Illumina's Vik Vaz to lead its commercialization. |
By Nick Paul Taylor Ex-NFL players and the CDC are about to “Gear Up Against Cancer,” kicking off a campaign that will see former footballers use their star power to raise awareness about screenings. |
By Kevin Dunleavy Bausch + Lomb has issued a statement saying that its board had authorized “management and its advisors to explore a potential sale, which is one of several options being explored to complete a full separation” from its parent, Bausch Health Companies. The statement came at the request of the Canadian Investment Regulatory Organization (CIRO), which wanted an explanation for the recent volatility in the company’s stock. |
By Darren Incorvaia LAB eN2, the drug discovery accelerator launched by Evotec and Novo Nordisk in September 2023, has unveiled its first three projects and launched an expansion featuring five new academic partners. |
By Nick Paul Taylor Ora has unveiled the next phase of its collaboration with the blind community, releasing a series of short films about the work of the Academy of Music for the Blind. |
By Fraiser Kansteiner Lonza unveiled a restructuring strategy under which the company will reorganize its CDMO business. Notably, Lonza aims to hive off its capsules and health ingredients business “at the appropriate time," the company said. |
By Gabrielle Masson Eye-focused biotechs Tenpoint Therapeutics and Visus Therapeutics are joining forces, setting their sights on filing a new drug approval application next year for a presbyopia-correcting eye drop. |
By Darren Incorvaia PeptiDream, the Japanese biopharma with a penchant for deal-making, has a new bargaining chip in hand in the red-hot obesity space. The firm’s oral macrocyclic peptides preserved lean muscle mass in mice given the weight-loss drug semaglutide. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," we explore the biotech IPO market rebound and ask: Is the momentum here to stay? |
|
|---|
|
|
|
The DMPK experts at QPS are ready to complete your next mass balance,
PK, ADME, MARG and/or QWBA study. Download the DMPK White Paper on the optimal methods of producing tissue distribution data and to learn more about QPS DMPK capabilities.
|
|
| WhitepaperWe interviewed 14 R&D biopharma leaders on the critical success factors for building a Best Practice R&D organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
| WhitepaperExplore the robust cross-platform agreement between scRNA-seq and bulk RNA-seq, ensuring consistent and reproducible data on immune cell presence. Sponsored by: IQVIA Laboratories |
| WhitepaperThe use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
| WhitepaperLearn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes. Presented by: Thermo Fisher Scientific |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
